期刊文献+

己糖激酶-Ⅱ在胃癌组织中的表达及其临床意义

Expression and clinical significance of hexokinase-Ⅱ in gastric cancer
下载PDF
导出
摘要 目的探讨己糖激酶-Ⅱ(HK-Ⅱ)在人体胃癌组织中的表达情况及其临床意义,分析HK-Ⅱ与临床病理特征之间的关系。方法选取2013年3—9月在东南大学医学院附属江阴医院确诊的胃癌病患100例,切除标本,运用免疫组化及RTPCR方法检测胃癌组织及正常胃黏膜组织中HK-Ⅱ的表达情况,并分析其与性别、年龄、浸润深度、TNM分期、分化程度、淋巴结转移、脉管侵犯、肿瘤大小等的关系。结果 HK-Ⅱ在胃癌组织中的阳性表达率为68.00%,显著高于正常胃黏膜组织(P<0.05)。HK-Ⅱ表达与性别、年龄、浸润深度无关(P>0.05);与TNM分期、分化程度、淋巴结转移、脉管侵犯、肿瘤大小有关(P<0.05)。胃癌组织HK-ⅡmRNA阳性率显著高于正常胃黏膜组织(P<0.01)。结论 HK-Ⅱ在胃癌组织中高表达,可作为胃癌的恶性预后指标和临床治疗靶点。 Objective To explore the expression and clinical significance of hexokinase-Ⅱ ( HK- Ⅱ ) in human gastric cancer tissues and to analyze its correlation with clinicopathological charac- teristics. Methods A total of 100 patients with gastric cancers from March to September 2013 were selected, and the expressions of HK- Ⅱ in gastric cancer tissues and normal gastric mucosa tissues were detected by immunohistochemical SP method and RT-PCR. The correlations between HK- Ⅱ and gen- der, age, depth of invasion, TNM staging, differentiated degree, lymphatic metastasis, vascular inva- sion and tumor size were analyzed. Results The positive expression rate of HK-Ⅱ in gastric cancer tissues was 68.00%, which was significantly higher than that in normal gastric mucosa tissues. The HK- Ⅱ expression was not associated with gender, age, depth of invasion ( P 〉 0.05 ), but was corre- lated with TNM staging, differentiated degree, lymphatic metastasis, vascular invasion and tumor size ( P 〈 0.05 ). The positive rate of HK- Ⅱ mRNA was significantly higher in gastric cancer tissues than that in normal gastric mucosa tissue (P 〈 0.01 ). Conclusion HK- Ⅱ, which is highly expressed in gastric cancer tissues, can be considered as malignant prognostic indicators and clinical therapeutic targets for gastric cancer.
出处 《实用临床医药杂志》 CAS 2015年第1期68-71,共4页 Journal of Clinical Medicine in Practice
基金 中国高校医学期刊临床专项资金(11321417)
关键词 己糖激酶-Ⅱ 胃癌 预后 逆转录聚合酶链反应 免疫组化 hexokinase-Ⅱ gastric cancer prognosis reverse transcriptase polymerase chain reaction immunohistochemistry
  • 相关文献

参考文献11

  • 1Garber K. Energy deregulation : licensing tumors to grow [ J ]. Science, 2006, 312(5777): 1158.
  • 2Pedersen P L. Warburg, me and Hexokinase 2: Multiple dis- coveries of key molecular events underlying one of cancers'most common phenotypes, the "Warburg Effect", ie, elevated gly- eolysis in the presence of oxygen [ J]. J Bioenerg Biomembr, 2007, 39(3) : 211.
  • 3彭秋平,梁后杰,周琪,周进明,傅晓岚,钟大平.己糖激酶-Ⅱ基因在人结肠癌细胞中的表达及其治疗意义[J].中华医学杂志,2007,87(15):1058-1062. 被引量:12
  • 4彭秋平,梁后杰,冯青青,柯传庆,刘红梅.HK-Ⅱ在结肠癌组织中的表达及其临床意义[J].肿瘤防治研究,2010,37(2):192-194. 被引量:1
  • 5邱成志,王川,吴友谊,朱世泽,张祥福.结直肠癌组织中Survivin表达与细胞增殖的关系[J].中国癌症杂志,2004,14(5):425-428. 被引量:2
  • 6Pedersen P L. The cancer cell's "power plants" as promising therapeutic targets: an overview [ J]. J Bioenerg Biomembr, 2007, 39(1): 1.
  • 7Pedersen P L, Mathupala S, Rempel A, et al. Mitochondrial bound type Ⅱ hexokinase: a key player in the growth and sur- vival of many cancers and an ideal prospect for therapeutic in- tervention [ J ]. Biochim Biophys Acta, 2002, 1555 ( 1/3 ) : 14.
  • 8Peng Q, Zhnn Q, Zhou J, et ah Stable RNA interference of hexnkinase Ⅱ gene inhibits human colon cancer LaVa eell growth invitroand in viva [ J ]. Cancer Biol Ther, 2008, 7 (7) : 1128.
  • 9张秀梅,张霞,肖建英.3-溴丙酮酸对肠癌HCT116细胞的增殖抑制作用及其机制[J].吉林大学学报(医学版),2013,39(3):525-528. 被引量:2
  • 10Wang F, Ogasawara M A, Huang P. Small mitochondfia-tar- geting molecules as anti-cancer agents [ J ]. Molecular aspects of medicine, 2010, 31 ( 1 ) : 75.

二级参考文献40

  • 1邱成志,王川,吴友谊,朱世泽,张祥福.结直肠癌组织中Survivin表达与细胞增殖的关系[J].中国癌症杂志,2004,14(5):425-428. 被引量:2
  • 2赵迎超,伍钢.己糖激酶与恶性肿瘤关系的研究进展[J].肿瘤防治研究,2006,33(9):694-696. 被引量:9
  • 3彭秋平,梁后杰,周琪,周进明,傅晓岚,钟大平.己糖激酶-Ⅱ基因在人结肠癌细胞中的表达及其治疗意义[J].中华医学杂志,2007,87(15):1058-1062. 被引量:12
  • 4Garber K. Energy deregulation: licensing tumors to grow [J]. Science, 2006, 312(5777) : 1158-1159.
  • 5Pedersen PL. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i. e. , elevated glycolysis in the presence of oxygen [J]. J Bioenerg Biomernbr, 2007, 39(3): 211-222.
  • 6Yasuda S, Arii S, Mori A, et al. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-indueible factor 1 alpha and its significance [J]. J Hepatol, 2004, 40 (1): 117-123.
  • 7Mathupala SP, Ko YH, Pedersen PL. Hexokinase II : cancer's double-edged sword acting as both facilitator and gate keeper of malignancy when bound to mitochondria [J]. Oncogene, 2006, 25(34): 4777-4786.
  • 8Burt BM, Humm JL, Kooby DA, et al. Using positron emis sion tomography with [(18)F]FFJG to predict tumor behavior in experimental colorectal cancer[J]. Neoplasia, 2001, 3(3): 189-195.
  • 9Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small invasive breast carcinomas [J]. Cancer Res, 1997, 57(7): 1259-1263.
  • 10Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitoehondrial respiratory defect and hypoxia [J]. Cancer Res, 2005, 65(2): 613-621.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部